Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 72 of 5804
-
Could a single drug replace chemo for some colon cancers?
Disease control Recruiting nowThe primary purpose of this study is to evaluate the efficacy of perioperative dostarlimab compared with standard of care (SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instability high (dMMR/MSI-H) colon cancer.
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Once-Daily pill shows promise for obesity in japanese patients
Disease control CompletedThe main purpose of this study is to investigate the efficacy and safety of oral orforglipron in participants with obesity disease with obesity-related health problems.
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New combo therapy takes on tough lymphoma
Disease control Recruiting nowThis phase II trial tests how well zanubrutinib and lisocabtagene maraleucel (liso-cel) work together in treating patients with Richter's syndrome that has come back (recurrent) or does not respond to treatment (refractory). Richter's syndrome occurs when chronic lymphocytic leuk…
Phase: PHASE2 • Sponsor: Aseel Alsouqi • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Double-Barreled CAR t takes on Hard-to-Treat myeloma
Disease control Recruiting nowThis trial is a Phase 1b/2, open-label, multicenter study of AZD0120, a CD19/BCMA dual CAR T-cell therapy, in adult subjects with relapsed/refractory multiple myeloma.
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Personalized mRNA vaccine shows promise in stopping melanoma return
Disease control OngoingThe purpose of this study is to learn if intismeran autogene which is an individualized neoantigen therapy (INT; formerly, called messenger ribonucleic acid \[mRNA\]-4157) with pembrolizumab (MK-3475) is safe and prevents cancer from returning in people with high-risk melanoma. R…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Engineered immune cells take on lupus and scleroderma
Disease control Recruiting nowThe investigational product is designed to effectively combat B cells in patients with autoimmune diseases. Autologous T cells enriched with CD4/CD8 are genetically engineered using a lentiviral vector to express chimeric antigen receptors (CARs) that target the CD19 antigen on t…
Phase: PHASE1, PHASE2 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Hope for rare brain disease: new drug trial aims to stall deadly decline
Disease control Recruiting nowA Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adults Male Subjects with Cerebral Adrenoleukodystrophy.
Phase: PHASE3 • Sponsor: Minoryx Therapeutics, S.L. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New weekly shot shows promise for obesity, knee pain, and sleep apnea
Disease control CompletedThe purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA) (J1I-MC-GOA1) or who have obstructive sleep apnea (OSA)…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New oral vaccine aims to shield infants from severe rotavirus
⭐️ VACCINE ⭐️ CompletedThis is a randomized, double-blind, phase 3 study to evaluate the Efficacy, Safety, and Immunogenicity of ROTAVAC 5D, a live attenuated rotavirus vaccine in healthy infants. A total of 5800 healthy Chilean infants will be recruited in this study and randomized to receive either …
Phase: PHASE3 • Sponsor: University of Chile • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 02, 2026 00:00 UTC
-
Can a vaccine stop stomach cancer from coming back?
⭐️ CURE ⭐️ OngoingThe purpose of this early proof-of-concept study to evaluate the safety and immunologic efficacy of AST-301 in gastric cancer patients with HER2 expression (including both HER2 low expression and overexpression) who have completed the standard adjuvant treatment (including those …
Phase: PHASE2 • Sponsor: Aston Sci. Inc. • Aim: ⭐️ CURE ⭐️
Last updated Jul 24, 2026 00:00 UTC
-
Double immune punch: new combo trial for tough lung cancer
Disease control OngoingThis study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab (also called REGN2810), individually called a "study drug" or collectively called "study drugs". The study is focused on patients who have advanced…
Phase: PHASE2, PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Stomach flu vaccine shows promise in massive Kids' trial
⭐️ VACCINE ⭐️ CompletedThe purpose of this study is to evaluate the Efficacy, Safety and Immunogenicity of the Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine,Recombinant (Hansenula polymorpha) in Healthy People Aged 6 Months to 13 Years After Vaccination
Phase: PHASE3 • Sponsor: National Vaccine and Serum Institute, China • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:11 UTC
-
New hope for lung cancer patients: experimental drug aims to extend life after other treatments fail
Disease control Recruiting nowThe goal of this Phase 3 clinical trial is to study the safety and efficacy of the nextgen anti-CTLA-4 antibody, gotistobart (ONC-392/BNT316), in patients with metastatic non-small cell lung cancer who have disease progressed on anti-PD-1/PD-L1 antibody based therapy. The study w…
Phase: PHASE3 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
First human trial of Gene-Edited lung cells for rare breathing disorder
Disease control Recruiting nowThe major goal of this study is to evaluate a new type of cell transplantation therapy for individuals with hereditary PAP, study a new treatment that may be useful for treatment of other diseases, and research mechanisms that drive the development and function of lung macrophage…
Phase: PHASE1, PHASE2 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Immunotherapy duo aims to boost lung cancer cure rates before surgery
Disease control Recruiting nowIn Cohort 1, the study was intended to assess safety and efficacy of neoadjuvant combination of IPH5201 and durvalumab in addition to standard chemotherapy and adjuvant combination of IPH5201 and durvalumab, in untreated patients with resectable, early-stage (stage II to IIIA) no…
Phase: PHASE2 • Sponsor: Innate Pharma • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug iberdomide takes on lenalidomide in battle to keep myeloma at bay
Disease control OngoingThe purpose of this study is to compare the effectiveness of iberdomide maintenance to lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly diagnosed multiple myeloma (NDMM).
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New combo therapy aims to beat back aggressive breast cancer
Disease control Recruiting nowThis is a randomized, open-label phase III clinical trial comparing antivascular therapy combined with standard chemotherapy and standard chemotherapy in adjuvant therapy for patients with triple-negative breast cancer, basal-like/Immune suppressed subtype.
Phase: PHASE3 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Stem cell therapy offers hope for children with butterfly skin
Disease control OngoingThe aim of this clinical trial is to investigate the safety and efficacy of allo-APZ2-OTS administered intravenously to subjects with recessive dystrophic epidermolysis bullosa (RDEB) compared to placebo. An additional baseline-controlled open-label arm will be included to invest…
Phase: PHASE3 • Sponsor: RHEACELL GmbH & Co. KG • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Gene therapy trial aims to help girls with rett syndrome gain new skills
Disease control OngoingThis study will evaluate the efficacy and safety profiles of the investigational gene therapy, NGN-401, in females with typical Rett syndrome.
Phase: PHASE3 • Sponsor: Neurogene Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New combo aims to boost lymphoma control in older patients
Disease control Recruiting nowThe goal of this clinical trial is to study the addition of Acalabrutinib to standard R-miniCHOP in older adults with DLBCL. The main question it aims to answer is whether progression free survival kann be prolonged with the addition of Acalabrutinib. Participants will be random…
Phase: PHASE3 • Sponsor: Universität des Saarlandes • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC